The study is a systematic review of US-approved vaccines against Covid-19, RSV and influenza based on a search of the PubMed/MEDLINE, Embase and Web of Science databases, updating previous ACIP reviews from 2023-2024[1]. Vaccines against the KP.2 subvariant of Covid-19 showed an efficacy of 68% (95% CI, 42 to 82) against hospitalization in a case-control study[1]. Maternal RSV vaccination (to protect infants), nirsevimab in infants, and RSV vaccines in adults older than 60 years were 68% or more effective against hospitalization[1]. Influenza vaccination had an overall effectiveness of 48% (95% CI, 39 to 55) in adults aged 18 to 64 years and 67% (95% CI, 58 to 75) in children against hospitalization[1]. The safety profiles of the vaccines are consistent with previous assessments; diagnosis of myocarditis associated with Covid-19 vaccines occurred at a rate of 1.3 to 3.1 per 100,000 doses in adolescent boys, with a lower risk at longer dosing intervals[1]. RSVpreF vaccine was associated with 18.2 excess cases of Guillain-Barré syndrome per million doses in older adults; a significant association with preterm birth was not observed when the vaccine was administered between 32 and 36 weeks of gestation[1]. Ongoing peer-reviewed evidence supports the safety and efficacy of these vaccinations during the 2025-2026 season[1].